Group One Trading
FDMT icon

Group One Trading’s 4D Molecular Therapeutics FDMT Stock Holding History

Group One Trading’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$176K Sell
18,900
-48,500
-72% -$422K ﹤0.01% 4220
2025
Q4 		$506K Buy
67,400
+26,800
+66% +$272K ﹤0.01% 3498
2025
Q3 		$353K Buy
40,600
+13,900
+52% +$83.1K ﹤0.01% 4057
2025
Q2 		$99.1K Buy
26,700
+5,300
+25% +$18.6K ﹤0.01% 4972
2025
Q1 		$69.1K Sell
21,400
-500
-2% -$2.36K ﹤0.01% 4906
2024
Q4 		$122K Buy
21,900
+10,500
+92% +$82.4K ﹤0.01% 4349
2024
Q3 		$123K Buy
11,400
+11,200
+5,600% +$186K ﹤0.01% 4005
2024
Q2 		$4.2K Sell
200
-5,200
-96% -$130K ﹤0.01% 6016
2024
Q1 		$172K Sell
5,400
-2,700
-33% -$68.9K ﹤0.01% 3694
2023
Q4 		$164K Buy
8,100
+8,000
+8,000% +$105K ﹤0.01% 4037
2023
Q3 		$1.27K Sell
100
-3,900
-98% -$65.2K ﹤0.01% 7170
2023
Q2 		$72.3K Buy
4,000
+2,400
+150% +$44.2K ﹤0.01% 4942
2023
Q1 		$27.5K Sell
1,600
-700
-30% -$13.6K ﹤0.01% 5305
2022
Q4 		$51.1K Buy
+2,300
New +$35.5K ﹤0.01% 4978
2022
Q1 		– Sell
-400
Closed -$9K – 8219
2021
Q4 		$9K Buy
+400
New +$9.8K ﹤0.01% 7393

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Group One Trading's FDMT Position: Q1 2026 in Review

Group One Trading opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 1,998 shares worth $18.6K. The stake represents ﹤0.01% of the portfolio and ranks #6011 among its holdings. This is a return to the name: Group One Trading previously reported a position in FDMT as recently as Q4 2024.

Group One Trading first reported a position in FDMT in Q4 2021 and has held it in 8 quarters since. The position peaked at $74.8K in Q4 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Group One Trading held 1,998 shares of 4D Molecular Therapeutics worth $18.6K as of Q1 2026.
  • 4D Molecular Therapeutics was a new Group One Trading position in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6011 holding.
  • Group One Trading first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • Group One Trading's 4D Molecular Therapeutics position peaked at $74.8K in Q4 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.